New targets for NAFLD

被引：140
作者：
Parlati, Lucia [1 ,2 ]
Regnier, Marion [3 ]
Guillou, Herve [4 ]
Postic, Catherine [1 ]
机构：
[1] Univ Paris, Inst Cochin, INSERM, CNRS, F-75014 Paris, France
[2] Hop Cochin, 24 Rue Faubourg St Jacques, F-75014 Paris, France
[3] Catholic Univ Louvain, UCLouvain, Walloon Excellence Life Sci & Biotechnol, Louvain Drug Res Inst,Metab & Nutr Res Grp, Brussels, Belgium
[4] Univ Toulouse, Toxalim, INRA, ENVT,INP Purpan,UPS, F-31027 Toulouse, France
来源：
JHEP REPORTS | 2021年 / 3卷 / 06期
关键词：
NAFLD; NASH; SREBP-1c; ChREBP; FXR; LXR; animal models; PPAR alpha; NEFA; glucotoxicity; lipotoxicity; NONALCOHOLIC FATTY LIVER; ACTIVATED RECEPTOR-ALPHA; DE-NOVO LIPOGENESIS; PPAR-ALPHA; OXIDIZED DIACYLGLYCEROL; FIBROSIS PROGRESSION; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC STEATOSIS; OBETICHOLIC ACID;
D O I：
10.1016/j.jhepr.2021.100346
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets. (C) 2021 Published by Elsevier B.V.
引用
收藏
页数：15
相关论文
共 138 条
  • [11] The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
    Barreyro, Fernando J.
    Holod, Silvia
    Finocchietto, Paola V.
    Camino, Alejandra M.
    Aquino, Jorge B.
    Avagnina, Alejandra
    Carreras, Maria C.
    Poderoso, Juan J.
    Gores, Gregory J.
    [J]. LIVER INTERNATIONAL, 2015, 35 (03) : 953 - 966
  • [12] The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
    Benhamed, Fadila
    Denechaud, Pierre-Damien
    Lemoine, Maud
    Robichon, Celine
    Moldes, Marthe
    Bertrand-Michel, Justine
    Ratziu, Vlad
    Serfaty, Lawrence
    Housset, Chantal
    Capeau, Jacqueline
    Girard, Jean
    Guillou, Herve
    Postic, Catherine
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (06) : 2176 - 2194
  • [13] The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
    Berg, AH
    Combs, TP
    Du, XL
    Brownlee, M
    Scherer, PE
    [J]. NATURE MEDICINE, 2001, 7 (08) : 947 - 953
  • [14] Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
    Biddinger, Sudha B.
    Hernandez-Ono, Antonio
    Rask-Madsen, Christian
    Haas, Joel T.
    Aleman, Jose O.
    Suzuki, Ryo
    Scapa, Erez F.
    Agarwal, Chhavi
    Carey, Martin C.
    Stephanopoulos, Gregory
    Cohen, David E.
    King, George L.
    Ginsberg, Henry N.
    Kahn, C. Ronald
    [J]. CELL METABOLISM, 2008, 7 (02) : 125 - 134
  • [15] Decoding cell death signals in liver inflammation
    Brenner, Catherine
    Galluzzi, Lorenzo
    Kepp, Oliver
    Kroemer, Guido
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (03) : 583 - 594
  • [16] The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity
    Bricambert, Julien
    Alves-Guerra, Marie-Clotilde
    Esteves, Pauline
    Prip-Buus, Carina
    Bertrand-Michel, Justine
    Guillou, Herve
    Chang, Christopher J.
    Vander Wal, Mark N.
    Canonne-Hergaux, Francois
    Mathurin, Philippe
    Raverdy, Violeta
    Pattou, Francois
    Girard, Jean
    Postic, Catherine
    Dentin, Renaud
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [17] Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis
    Cazanave, S. C.
    Wang, X.
    Zhou, H.
    Rahmani, M.
    Grant, S.
    Durrant, D. E.
    Klaassen, C. D.
    Yamamoto, M.
    Sanyal, A. J.
    [J]. CELL DEATH AND DIFFERENTIATION, 2014, 21 (08) : 1303 - 1312
  • [18] Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
    Chakravarthy, Manu V.
    Lodhi, Irfan J.
    Yin, Li
    Malapaka, Raghu R. V.
    Xu, H. Eric
    Turk, John
    Semenkovich, Clay F.
    [J]. CELL, 2009, 138 (03) : 476 - 488
  • [19] Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
    Chalasani, Naga
    Abdelmalek, Manal F.
    Garcia-Tsao, Guadalupe
    Vuppalanchi, Raj
    Alkhouri, Naim
    Rinella, Mary
    Noureddin, Mazen
    Pyko, Maxmillan
    Shiffman, Mitchell
    Sanyal, Arun
    Allgood, Adam
    Shlevin, Harold
    Horton, Rex
    Zomer, Eliezer
    Irish, William
    Goodman, Zachary
    Harrison, Stephen A.
    Traber, Peter G.
    [J]. GASTROENTEROLOGY, 2020, 158 (05) : 1334 - +
  • [20] The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
    Chalasani, Naga
    Younossi, Zobair
    Lavine, Joel E.
    Diehl, Anna Mae
    Brunt, Elizabeth M.
    Cusi, Kenneth
    Charlton, Michael
    Sanyal, Arun J.
    [J]. GASTROENTEROLOGY, 2012, 142 (07) : 1592 - 1609
12345678910